drugset / Trial / NCT06644417
Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is a phase II multicenter, randomized, double-blind, placebo controlled study designed to evaluate the efficacy and safety in LLV subjects and demonstrate that TQA3605 tablets combined with oral NAs drugs can improve the efficacy and safety of LLV subjects compared with oral NAs drug.
Timeline
- Start
- 2024-11-14
- Primary completion
- 2025-08-25
- Completion
- 2025-12-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQA3605 | Unknown | 100 mg | — |
| Subject | TQA3605 | Unknown | 200 mg | — |